Memorial Hospital Research Laboratories
The Jason Lewis Lab
Research
The Lewis lab research interests are focused on the development of radiopharmaceuticals for targeted diagnosis and treatment of cancer. By combining small- and biomolecule-based targeting agents with positron-emitting or therapeutic radioisotopes, we can interrogate molecular profiles of cancer using noninvasive nuclear imaging or treat tumors specifically with endoradiotherapy. Our research program is a molecular-imaging-based program focused on the targeting of nonstandard nuclides, with an emphasis on developing these novel radiopharmaceuticals for clinical translation. A few examples of our work are given below.
Featured News
Publications Highlights
People
Jason S. Lewis, PhD
Emily Tow Chair in Oncology
- Radiochemist Jason Lewis develops molecular imaging agents for the imaging and therapy of cancer.
- PhD, The University of Kent (UK)
- [email protected]
- Email Address
- 646-888-3038
- Office Phone
- View physician profile
- Physician profile
Members
- University of Maryland, Baltimore County (UMBC)
- BS in Chemistry
- MD
- 770-861-3438
- Office Phone
- BS in chemistry
- MD
Lab Alumni
Lab Affiliations
Achievements
- 2023 ACS - Glenn T. Seaborg Award for Nuclear Chemistry
- 2021 Gold Medal for Lifetime Achievement, World Molecular Imaging Society
- 2020 American Chemical Society Bioconjugate Chemistry Lecture Award
- Paul C. Aebersold Award, ERF-SNMMI (2019)
- NCI R35 Outstanding Investigator Award (2019-2026)
Read more
- Fellow, Society of Nuclear Medicine and Molecular Imaging (FSNMMI) (2019)
- Michael J. Welch Award, SNMMI (2017)
- Fellow, World Molecular Imaging Society (FWMIS) (2015)
- Distinguished Investigator Award, Academy Radiology Research (2014)
Get in Touch
-
Lab Head Email
-
Office Phone
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Jason S. Lewis discloses the following relationships and financial interests:
-
Alpha-9 Theranostics Inc.
Equity; Professional Services and Activities -
CSRA Inc.
Professional Services and Activities -
CheMatech
Intellectual Property Rights -
Clarity Pharmaceuticals
Equity; Professional Services and Activities -
Daiichi Sankyo
Intellectual Property Rights -
Diaprost AB
Intellectual Property Rights -
Earli Inc.
Professional Services and Activities -
Elsevier
Professional Services and Activities -
Elucida Oncology
Intellectual Property Rights -
Evergreen Theragnostics
Equity; Professional Services and Activities (Uncompensated) -
Inhibrx, Inc.
Professional Services and Activities
-
Journal of Nuclear Medicine
Professional Services and Activities -
Nextech Venture, LTD
Professional Services and Activities -
Samus Therapeutics LLC
Intellectual Property Rights -
Suba Therapeutics, Inc.
Equity; Professional Services and Activities -
Summit Biomedical Imaging, LLC
Equity -
TPG Capital
Professional Services and Activities -
Telix Pharmaceuticals Limited
Equity; Professional Services and Activities (Uncompensated) -
Theragnostics, Ltd.
Intellectual Property Rights -
Trace-Ability, Inc.
Equity -
World Molecular Imaging Society
Professional Services and Activities -
pHLIP, Inc.
Equity; Intellectual Property Rights; Professional Services and Activities
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].